orforglipron
Jump to navigation
Jump to search
Indications
- adults with type 2 diabetes (investigational)
Dosage
- 3 mg, 12 mg, or 36 mg once daily
Adverse effects
Notes
- lowers HgbA1c 1.2-1.5%
- reduces weight 4.5% (3-mg), 5.8% (12-mg) 7.6% (36-mg)
More general terms
References
- ↑ Rosenstock J, Hsia S, Nevarez Ruiz L, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. 2025 Jun 21. PMID: https://pubmed.ncbi.nlm.nih.gov/40544435 https://www.nejm.org/doi/10.1056/NEJMoa2505669
- ↑ Horn DB, Ryan DH, Kis SG, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2025 Nov 20:S0140-6736(25)02165-8 PMID: https://pubmed.ncbi.nlm.nih.gov/41275875